Agenus: Attractive Entry Level after Recent Pullback
This year, Agenus (AGEN) stock has fluctuated widely. The clinical-stage biotechnology company’s stock fell from $3.88 in February to about $2.12 in August.
Will Genocea Stock Bounce Back? In-Depth Analysis
Today, we’re taking a close look at Genocea (GNCA) to show why the stock could bounce back after fluctuating significantly over the last year.
Incyte Advances R&D Strategy with Multiple Partnerships
In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN).
Who Is Incyte Collaborating With?
Incyte’s (INCY) Jakafi is distributed in the United States through a network of specialty pharmacy providers and wholesalers for direct delivery.
Profit Taking in XBI Holdings Pulled the Fund Down
The SPDR S&P Biotech ETF (XBI) fell by 1.1% to close at $51.72 and was trading above the 20-day moving average price of $48.7.